Search results for: Oncology
Filter search results
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe. OHE’s Adrian Towse participated in a two-day workshop convened…
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
…of the first HTA bodies in the world. This evolved into the Canadian Agency for Drugs and Technology in Health (CADTH) in 2006. CADTH administered the pan-Canadian Oncology Drug Review…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Share this: Download publication Henry Fong Priscila Radu Nadine Henderson Martina Garau Lotte Steuten Key messages Tumour-agnostic (TA) therapies disrupt conventional oncology paradigms by targeting molecular alterations rather than tumour…
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…and more unintended consequences in the long term. Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology, co-authored by Adrian Towse (OHE), Dr Mickael Lothgren…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…the drugs treat more than one condition. Two of the drugs are used to treat autoimmune disorders such as psoriasis, rheumatoid arthritis and Crohn’s disease. There is only one oncology…
Unlocking the Value of Combination Therapies
9 July 2024
…CTs are increasingly being used in oncology. Key takeaways The current approach to attributing value to therapies used in combination is the incremental value (IV) approach. However, this method faces…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…medicine (a “follow-on” indication). This represents a hugely important and growing route to new treatment options for many patients, particularly in oncology, immunology, and rare diseases, among others. Adopting policies…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…grow, adopting OBIs in cancer care represents a strategic opportunity to build on existing benefits of SC drug delivery, and further advance efficiency, sustainability, and patient-centred service delivery across oncology….
OHE at ISPOR Europe: Posters
13 November 2014
…Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014 from Office of Health Economics Koonal Shah and Brendan Mulhern (University of Sheffield) The Expanding Value Footprint of Oncology Treatments. Ispor poster expanding_value_footprint_oncology_treatment_jmf_oct2014 from Office of…